Literature DB >> 12618088

A novel point mutation (I137T) in the conserved 5-phosphoribosyl-1-pyrophosphate binding motif of hypoxanthine-guanine phosphoribosyltransferase (HPRTJerusalem) in a variant of Lesch-Nyhan syndrome.

Esther Zoref-Shani1, Yael Bromberg, Joel Hirsch, Sofia Feinstein, Yaacov Frishberg, Oded Sperling.   

Abstract

We identified a novel point mutation (I137T) in the hypoxanthine-guanine phosphoribosyltransferase (HPRT; EC 2.4.2.8) encoding gene, in a patient with partial deficiency of the enzyme (variant of Lesch-Nyhan syndrome). The mutation, ATT to ACT, resulting in substitution of isoleucine to threonine, occurred at codon 137 (exon 6), which is within the region encoding the binding site for 5-phosphoribosyl-1-pyrophosphate (PRPP). We suggest the mechanism by which the mutation-induced structural alteration of HPRT reduced the affinity of the enzyme for PRPP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618088     DOI: 10.1016/s1096-7192(03)00002-7

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  3 in total

Review 1.  Viral infection and human disease--insights from minimotifs.

Authors:  Krishna Kadaveru; Jay Vyas; Martin R Schiller
Journal:  Front Biosci       Date:  2008-05-01

2.  Phenotypic variation among seven members of one family with deficiency of hypoxanthine-guanine phosphoribosyltransferase.

Authors:  Irène Ceballos-Picot; Franck Augé; Rong Fu; Anne Olivier-Bandini; Julie Cahu; Brigitte Chabrol; Bernard Aral; Bérengère de Martinville; Jean-Paul Lecain; H A Jinnah
Journal:  Mol Genet Metab       Date:  2013-09-08       Impact factor: 4.797

Review 3.  Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder.

Authors:  Rong Fu; Irene Ceballos-Picot; Rosa J Torres; Laura E Larovere; Yasukazu Yamada; Khue V Nguyen; Madhuri Hegde; Jasper E Visser; David J Schretlen; William L Nyhan; Juan G Puig; Patrick J O'Neill; H A Jinnah
Journal:  Brain       Date:  2013-08-22       Impact factor: 13.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.